Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investing In Life Sciences De Novo

This article was originally published in Start Up

Executive Summary

In the last two years, several major venture capital firms that had previously been major investors in life sciences companies abandoned health care for the rarified worlds of information technology and telecommunications. This created a void in health care investing that has seen two venture firms formed recently to focus exclusively on life sciences. First was Versant Ventures (formerly Palladium), which was started in September 1999 by the life sciences partners from Brentwood, IVP and Crosspoint Ventures. And more recently, in February 2000, four veterans of the life science investing wars--John Simpson, MD, Fred Dotzler, Richard Ferrari and David Mauney, MD--got together to form De Novo Ventures, which is also health care-focused. In addition to providing financing, De Novo is also looking to take advantage of the extensive operational experience of its partners by providing start-ups with hands-on management expertise.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts